MX340738B - Terapia para deficiencia de a-galactosidasa a. - Google Patents

Terapia para deficiencia de a-galactosidasa a.

Info

Publication number
MX340738B
MX340738B MX2014010892A MX14010892A MX340738B MX 340738 B MX340738 B MX 340738B MX 2014010892 A MX2014010892 A MX 2014010892A MX 14010892 A MX14010892 A MX 14010892A MX 340738 B MX340738 B MX 340738B
Authority
MX
Mexico
Prior art keywords
galactosidase
deficiency
therapy
human
gal
Prior art date
Application number
MX2014010892A
Other languages
English (en)
Spanish (es)
Inventor
F Selden Richard
Borowski Marianne
P Gillespie Frances
M Kinoshita Carol
A Treco Douglas
D Williams Melanie
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX340738B publication Critical patent/MX340738B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
MX2014010892A 1996-09-13 1997-09-12 Terapia para deficiencia de a-galactosidasa a. MX340738B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71261496A 1996-09-13 1996-09-13
PCT/US1997/016603 WO1998011206A2 (en) 1996-09-13 1997-09-12 THERAPY FOR α-GALACTOSIDASE A DEFICIENCY

Publications (1)

Publication Number Publication Date
MX340738B true MX340738B (es) 2016-07-22

Family

ID=24862863

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010892A MX340738B (es) 1996-09-13 1997-09-12 Terapia para deficiencia de a-galactosidasa a.

Country Status (20)

Country Link
EP (4) EP0935651B1 (pl)
JP (7) JP4001925B2 (pl)
KR (2) KR100547402B1 (pl)
CN (1) CN1268741C (pl)
AT (1) ATE286120T1 (pl)
AU (1) AU4424497A (pl)
CA (1) CA2265464C (pl)
DE (1) DE69732129T2 (pl)
DK (2) DK1538202T3 (pl)
ES (3) ES2581828T3 (pl)
HU (2) HU230275B1 (pl)
IL (2) IL128960A (pl)
MX (1) MX340738B (pl)
NO (4) NO328443B1 (pl)
NZ (2) NZ506214A (pl)
PL (1) PL190041B1 (pl)
PT (1) PT1538202E (pl)
RU (1) RU2179034C2 (pl)
TW (1) TW585919B (pl)
WO (1) WO1998011206A2 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL135578A0 (en) * 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
EP1658857A1 (en) * 1997-10-29 2006-05-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2004242550B2 (en) * 1999-03-11 2008-04-03 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) * 1999-03-11 2016-07-28 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2016250357B2 (en) * 1999-03-11 2018-11-01 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
WO2002064799A2 (en) 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
EP2275559A3 (en) * 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
ES2328446T5 (es) 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
EP1503788B1 (en) 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
BRPI0618583A2 (pt) * 2005-11-18 2011-09-06 Tokyo Metropolitan Org Med Res enzima altamente funcional tendo especifidade ao substrato modificada
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
HRP20120994T1 (hr) 2006-02-07 2012-12-31 Shire Human Genetic Therapies, Inc. Stabilizirana smjesa glukocerebrozidaze
DK1988823T3 (en) 2006-02-09 2018-12-03 Genzyme Corp SLOW INTRAVENTRICULAR ADMINISTRATION
EP2166093B1 (en) 2007-05-18 2015-09-16 Tokyo Metropolitan Institute of Medical Science Pharmaceutical composition for enzyme replacement therapy
CA3040973A1 (en) 2008-12-16 2010-07-01 Genzyme Corporation Oligosaccharide-protein conjugates
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
PT2561069T (pt) 2010-04-23 2017-05-22 Alexion Pharma Inc Enzima de doença de armazenamento lisossomal
WO2012012461A2 (en) 2010-07-19 2012-01-26 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
CA2810999C (en) 2010-09-09 2023-10-03 Anthony Quinn Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
BR112014010406A2 (pt) * 2011-11-02 2017-04-25 Genentech Inc cromatografia de sobrecarga e eluto
WO2013130963A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
RU2015102810A (ru) * 2012-06-29 2016-08-20 Консехо Супериор Де Инвестигасионес Сьентификас (Ксис) Функционализированные липосомы, пригодные для доставки биоактивных соединений
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
US20150275195A1 (en) 2012-10-24 2015-10-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
TW202332774A (zh) 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
FI3237621T3 (fi) * 2014-12-22 2023-06-01 Codexis Inc Ihmisen alfa-galaktosidaasivariantteja
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
GB201508025D0 (en) * 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CN116270739A (zh) 2017-06-30 2023-06-23 富士胶片株式会社 细胞结构体在制造溶酶体贮积病处置剂中的用途
ES2716305B2 (es) 2017-12-11 2019-11-27 Fund Biomedica Galicia Sur Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
SG11202106348QA (en) 2018-12-20 2021-07-29 Codexis Inc Human alpha-galactosidase variants
CN111308095A (zh) * 2020-03-04 2020-06-19 北京师范大学 用于诊断前列腺癌的尿液蛋白标记物
WO2024044697A2 (en) * 2022-08-24 2024-02-29 Walking Fish Therapeutics, Inc. Compositions and methods for treatment of fabry disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2619719B1 (fr) * 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
DK555488A (da) * 1987-10-02 1989-06-14 Zymogenetics Inc Sekretionssignal
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
IL95330A0 (en) * 1989-08-11 1991-06-30 Lilly Co Eli Expression of a functional insect specific toxin gene in mammalian cells
EP0550675A1 (en) * 1990-09-28 1993-07-14 Cephalon, Inc. Transgenic animals with alzheimer's amyloid precursor gene
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
JPH06503479A (ja) * 1991-10-16 1994-04-21 オラージェン，　インコーポレイテッド 動物体細胞の粒子−媒介トランスフォーメーション
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
EP0726944B1 (en) * 1993-07-02 2002-12-18 Incyte Pharmaceuticals, Inc. Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
AU681240C (en) 1994-01-13 2006-12-07 Rogosin Institute, The Macroencapsulated secretory cells
JP2984552B2 (ja) * 1994-09-02 1999-11-29 大和化成株式会社 ラッカーゼおよびその生産方法
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JPH08196293A (ja) * 1995-01-25 1996-08-06 Mitsui Toatsu Chem Inc タンパク質の製造方法
CN1161468C (zh) * 1995-02-15 2004-08-11 安姆根有限公司 Mpl配体类似物

Also Published As

Publication number Publication date
EP2374876B1 (en) 2016-04-13
JP4313405B2 (ja) 2009-08-12
EP2327775A2 (en) 2011-06-01
CA2265464C (en) 2007-06-26
KR20050084473A (ko) 2005-08-26
NO991225D0 (no) 1999-03-12
HK1162580A1 (en) 2012-08-31
EP2374876A3 (en) 2012-10-24
JP2015044830A (ja) 2015-03-12
JP4001925B2 (ja) 2007-10-31
JP2012019793A (ja) 2012-02-02
NO330687B1 (no) 2011-06-06
EP2327775A3 (en) 2012-10-24
EP0935651B1 (en) 2004-12-29
NZ334721A (en) 2001-01-26
EP1538202B1 (en) 2014-01-22
JP2009060918A (ja) 2009-03-26
IL184637A (en) 2015-07-30
ATE286120T1 (de) 2005-01-15
NZ506214A (en) 2002-11-26
CN1268741C (zh) 2006-08-09
JP2009102321A (ja) 2009-05-14
IL184637A0 (en) 2009-09-22
NO20141168L (no) 1999-05-10
HU230275B1 (hu) 2015-11-30
HU1000445D0 (en) 2010-11-29
DK1538202T3 (en) 2014-03-24
ES2234032T3 (es) 2005-06-16
RU2179034C2 (ru) 2002-02-10
EP0935651A2 (en) 1999-08-18
NO991225L (no) 1999-05-10
WO1998011206A3 (en) 1998-08-13
PT1538202E (pt) 2014-04-22
NO328443B1 (no) 2010-02-22
EP1538202A2 (en) 2005-06-08
JP2001504324A (ja) 2001-04-03
ES2581828T3 (es) 2016-09-07
TW585919B (en) 2004-05-01
KR20000036078A (ko) 2000-06-26
AU4424497A (en) 1998-04-02
PL332188A1 (en) 1999-08-30
HK1074058A1 (en) 2005-10-28
JP2007289201A (ja) 2007-11-08
NO340408B1 (no) 2017-04-18
CN1230220A (zh) 1999-09-29
KR100547402B1 (ko) 2006-02-01
JP5590788B2 (ja) 2014-09-17
EP1538202A3 (en) 2007-05-30
DE69732129T2 (de) 2005-12-08
HUP9904666A3 (en) 2001-09-28
IL128960A0 (en) 2000-02-17
DK2374876T3 (en) 2016-05-30
NO20110496L (no) 1999-05-10
HU9904666A (en) 2000-05-28
WO1998011206A2 (en) 1998-03-19
DE69732129D1 (de) 2005-02-03
HU227189B1 (en) 2010-10-28
PL190041B1 (pl) 2005-10-31
NO20090583L (no) 1999-05-10
JP2007000145A (ja) 2007-01-11
IL128960A (en) 2007-10-31
ES2458292T3 (es) 2014-04-30
JP4313381B2 (ja) 2009-08-12
HK1022173A1 (zh) 2000-07-28
EP2374876A2 (en) 2011-10-12
CA2265464A1 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
MX340738B (es) Terapia para deficiencia de a-galactosidasa a.
EP0923293A4 (en) DIARRHEA TREATMENT
AU6760987A (en) Method of treating alzheimer's disease
IL130083A0 (en) 3-Pyridyl enantiomers and their use as analgesics
IN167680B (pl)
PT2143420E (pt) Formulação contendo um ou mais mutantes da alfa-galactosidade a lisossomal para o tratamento da doença de fabry
NO883540L (no) Fremgangsmaate og anlegg for behandling av slam.
DK505787D0 (da) Catecholderivater samt forebyggende og terapeutisk praeparat omfattende samme mod regressive sygdomme i centralnervesystemet
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
AU5323396A (en) Methods of treating inflammation and compositions therefor
IL81857A (en) Insecticidal compositions for controlling scarabid larvae,containing bacterial spored of milky disease bacillus free of sporangia,and in vitro method for producing such spores
DK1225906T3 (da) Mekanisk forlængede nerveceller og fremgangsmåde til at producere og anvende disse celler
EP0246223A4 (en) PRODUCTION INCREASED AND STIMULATING AGENTS FOR MICROBIAL PLANTS.
EP0354323A3 (en) Antidiabetic phosphates
UA26870C2 (uk) Спосіб підвищеhhя продукуваhhя протеїhу с, спосіб підвищеhhя рівhя його модифікації
IL131478A0 (en) Methods for treatment of scar tissue
EP0904094A4 (en) TREATMENT OF BONE DISEASES WITH ADRENOMEDULLIN
CS275028B2 (en) Method of animal leather treatment and equipment for its realization
AU2816889A (en) Method for treatment of dyslipidemia in humans
EP0692969A4 (en) METHOD FOR TREATING DISEASES BY DELETING T CELLS
AU1678188A (en) Post harvest treatment of produce
UA7955A (uk) Спосіб лікування туберкульозу легенів
MX9405923A (es) Mejoras en proceso para humectar y suavizar la piel.
UA10130A (uk) Спосіб стимулювання проліферативної активності клітин кісткового мозку у летально опромінених тварин
OA07909A (fr) Nouveaux arylamino-1 amino-3 propanols-2 diversement substitués, leur méthode de préparation et leur application en thérapeutique.